Amgen Enters Anti-Obesity Drug Race

Amgen sign and STAT logo

New medication delivers promising results in Phase 1 trial

A “14.5% total body weight loss certainly looks promising!” Katherine Saunders, an obesity specialist and founder of the obesity-focused telehealth company Intellihealth, wrote in an email.

Read more at STAT or at The Advisory Board.

Related News